Antibodies targeting tl1a and uses thereof
By developing antibodies that specifically bind to TL1A and block its interaction with DR3, the problems of unsustainable efficacy and drug resistance in existing treatments for autoimmune diseases have been solved. This has enabled the effective inhibition of Th1, Th2, and Th17-mediated inflammatory responses and fibrosis processes, providing a new treatment option.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- 星锐医药(苏州)有限公司
- Filing Date
- 2026-06-01
- Publication Date
- 2026-06-30
AI Technical Summary
Existing drugs for treating autoimmune diseases have short-lasting efficacy, high drug resistance, increased risk of infection, and cannot effectively control fibrosis. Some patients do not respond or respond poorly to existing therapies, and there is an urgent need for new targeted therapy strategies.
Develop antibodies that specifically bind to TL1A and block its interaction with DR3. By specifically blocking the interaction between TL1A and DR3, Th1, Th2, and Th17-mediated inflammatory responses and fibrotic processes can be inhibited.
It significantly improves endoscopic healing, increases clinical remission rates, has good safety profile, provides new treatment options, and offers an effective treatment plan for patients who do not respond to or are intolerant of existing treatments.
Smart Images
Figure CN122302066A_ABST